Threshold Pharmaceuticals News

Threshold Pharmaceuticals, Inc. today announced preclinical results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented today at the American Society of Hematology Meeting being held December 5 to 8, 2009, in New Orleans, LA.

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 15 to 19, 2009, in Boston, MA.

Threshold Pharmaceuticals, Inc. today announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The presentation was made at the Chemotherapy Foundation Symposium taking place in New York City from November 10 to 14, 2009.

Threshold Pharmaceuticals Inc., a development-stage biotechnology company, said late Thursday its third-quarter loss widened on higher research, development, and interest expenses.

Threshold Pharmaceuticals , developer of treatments for tumors, has fallen on tough times after going public in 2005.

October 6, 2009 Threshold Pharmaceuticals, Inc. trading at $9.09 on a volume of 14,435 shares.

Threshold Pharmaceuticals, Inc. , today announced that it has entered into a securities purchase agreement with a select group of new investors that includes Federated Kaufmann Fund , Frazier Healthcare Ventures and Great Point Partners, LLC plus several of the Company's existing institutional investors and certain members of management, for the ...

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology taking place in Berlin, Germany from September 20 to 24, ...

Nuveta Inc , a medical device company that focuses on in vitro fertilization research, said Wednesday it closed a seed financing round.

Threshold Pharmaceuticals, Inc. and the Virginia G. Piper Cancer Center at Scottsdale Healthcare announced yesterday clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the World Conference on Lung Cancer being held July 31 to August 4, 2009, at the Moscone Convention Center ...

Threshold Pharmaceuticals, Inc. and the Virginia G. Piper Cancer Center at Scottsdale Healthcare announced yesterday clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the World Conference on Lung Cancer being held July 31 to August 4, 2009, at the Moscone Convention Center ...